cyrilzakka/clinical-trials huggingface dataset:
Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma

The pattern of lower airway inflammation in asthma is heterogeneous, but in many patients, the polymorphonuclear neutrophil (PMN) is the predominant granulocyte infiltrating the airspaces. Although it is known to have an important function in innate immune defense, the role of the PMN in asthma has not been well elucidated. In work in progress, the investigators have identified the receptor for IL-5 on the surface of bronchoalveolar lavage (BAL) PMNs in a subset of children with severe, treatment-resistant asthma, a characteristic that is not found in peripheral blood neutrophils. While the function of this IL-5 receptor has yet to be determined, preliminary evidence strongly supports a mechanism linking neutrophilic with type 2 inflammation in the lower airways of children with asthma, a discovery that has exciting potential to modify the treatment of asthma.

The primary objective of this observational cross-sectional study is to test the overall hypothesis that therapeutic intervention directed against the IL-5R on lung PMNs will decrease inflammation and improve clinical outcomes in patients with poorly controlled asthma. The secondary study objective is to demonstrate that IL-5R expression on lung-infiltrating PMNs is functional, will activate known IL-5R-induced signaling pathways, and will lead to enhanced PMN pro-inflammatory activity including increased PMN recruitment, prolonged survival, degranulation, and release of reactive oxygen species.


Eligibility Criteria:
Inclusion Criteria:

* Ages 0-17
* Treatment-resistant, refractory respiratory symptoms
* Scheduled for a clinical diagnostic bronchoscopy

Exclusion Criteria:

* Known lower respiratory tract infection within 60 days of scheduled bronchoscopy
* Systemic disorders involving the heart, respiratory system, CNS, renal, and endocrine systems
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.


Eligibility Criteria:
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has body mass index (BMI) ≥25 kg/m\^2 (≥23 kg/m\^2 for Asian participants) AND has stable weight, defined as ≤5% gain or loss of body weight for at least 3 months before screening
* Has no history of type 2 diabetes mellitus (T2DM) OR has a history of T2DM with a glycated hemoglobin (A1C) ≤9% AND the T2DM is controlled by diet or stable doses of oral antihyperglycemic agents (AHAs)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following

* Has a history or evidence of chronic liver disease other than Metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic dysfunction-associated steatohepatitis (MASH)
* Has evidence of decompensated liver disease including, but not limited to ascites, esophageal or gastric variceal bleeding, hepatocellular carcinoma, hepatic encephalopathy, splenomegaly, or spontaneous bacterial peritonitis
* Has a history of pancreatitis
* Has a history of type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy.
* Has symptomatic hyperglycemia
* Has a history of a bariatric surgical procedure ≤5 years before Screening or a known clinically significant gastric emptying abnormality
* Has a history of obesity with a known secondary cause
* Has significant systemic or major illnesses, including recent (≤6 months before Screening) onset of events of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack
* Is unable to have Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) due to: Claustrophobia to a degree that prevents tolerance of an MRI-PDFF scanning procedure. Note: Sedation is permitted, at the discretion of the investigator; Metallic implants that prevent MRI-PDFF examination; Exceeds the body habitus and/or weight limitations for the MRI scanner
Weight Loss Through Mayo Clinic Diet

The purpose of study is to evaluate the efficacy of the Mayo Clinic Diet in clinically significant weight loss (\>5%) versus usual care. We also wish to evaluate the feasibility, barriers to completion, and sustainability of this intervention at the 24, and 52-week marks. Lastly, we aim to study the change in participants body composition and quality of life at the end of this intervention.


Eligibility Criteria:
Inclusion Criteria:

* Males and females (non-pregnant) 18-64
* BMI \> or = to 25 kg/m2
* Ability to read and understand English. (as the Mayo Clinic Diet book and app are only available in English)

Exclusion Criteria:

* Have a current diagnosis of melanoma or cancer diagnosis
* Currently breastfeeding
* Pregnant, or planned to be pregnant within 6 months
* Have a diagnosis of Type 1 or 2 Diabetes Mellitus
* Are taking weight loss medications or had weight loss surgery within the last year
* Currently participating in another lifestyle weight loss program
* Have a history of eating disorders
* Have planned surgery in the next 6 months.
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)

The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID. Patients included have Osteoarthritis, Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient questionnaires.

Cross-sectional, observational Real Life study on NSAIDs treated patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of patient adherence to PPI treatment

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis (documented in the medical record) of OA, RA or AS
* Prescription of oral NSAID treatment for OA, RA or AS, where low dose is not sufficient
* Prescription of PPI for prevention of NSAID associated GI ulcers, with instruction to take PPI same day as when taking NSAID.

Exclusion Criteria:

* Participating in any clinical trial involving PPI or NSAID
* Patients prescribed PPI as acute treatment of GI events or symptoms within 8 weeks
* Inability to complete PROs
Arrhythmias, Microalbuminuria and Corticosteroids

The goal of this observational design is to study the effects of intravenous corticosteroids on heart rate variability, arrhythmias and microalbuminuria. Some previous studies have shown that intravenous corticosteroids could induce bradycardia but also supra-ventricular tachycardia and atrial fibrillation.

A second goal of this study is to investigate whether exogenous corticosteroids may induce microalbuminuria. A large retrospective study has revealed an association between microalbuminuria and corticosteroid use in the year preceding the measurement.

On intra-hospital patients, it will be explored the prevalence of arrythmias, the heart rate variability and the modification of the microalbuminuria level after intravenous infusion of corticosteroids. The investigator shall not initiate the treatment. Patients will receive high-dose intravenous corticosteroids for the treatment of different diseases. The departments, where the patients are enrolled, are: nephrology, neurology, dermatology and rheumatology and the day hospital. The day before the corticosteroids administration, a holter monitor will be started for at least 24h to detect arrhythmias and heart rate variations. By mean of a Finometer, beat-to-beat blood pressure, cardiac output and baroreflex sensitivity will be measured before, during and after the infusion. Blood and urine samples will be used to explore the effects of corticosteroids on microalbuminuria, electrolytes, CRP and glomerular filtration rate during the 3 days of observation.

To our knowledge, it will be the first prospective trial to explore a link between intravenous corticosteroids administration and heart rate variability, Baroreflex Sensitivity, as well as microalbuminuria.

Eligibility Criteria:
Inclusion Criteria:

* Starting high-dose intravenous corticotherapy

Exclusion Criteria:

* None
Effectiveness of Robot-assisted Rehabilitation in Persons With Stroke

This study is to investigate the effects of robot-assisted hand with visual feedback intervention on cortical excitability, brain structure, spasiticity, gross and fine motor of upper limb and hand in individuals with stroke. Twenty participants will be recruited in this study. They will be allocated to two group: robot-assisted hand combined with traditional occupational therapy group (10), only traditional occupational therapy group (10).

Participants will be randomized allocated to two groups: robot-assisted hand combined with traditional occupational therapy (OT) group and traditional OT group. All participants underwent six weeks, 3 sessions per week, and 60 minutes per session training program. Motor Evoked Potential (MEP), Fugl-Meyer Assessment (FMA), Modified Ashworth Scale (MAS), Box and Block Test (BBT) and Purdue Pegboard Test (PPT) will be assessed before and after intervention in all participants.

Eligibility Criteria:
Inclusion Criteria:

1. Mini-Mental State Examination score is above 23
2. A first-ever stroke with unilateral hemiplegia or hemiparesis.
3. Medical and psychological condition is stable.

Exclusion Criteria:

1. Balance and walking ability affected by other neurological problems
2. Functional performance affected by medication or medical condition 3 Unable to tolerate rehabilitation.

4. Severe hearing or visual problem. 5. Having pacemaker.
Safety and Performance Evaluation of the Rapid Ring Device

The purpose of this study is to demonstrate the safety, performance and initial efficacy of the RapiDx device.

The study will be a single center, open label, prospective, non-comparative, randomized trial and assess the safety and performance of the Rapid Ring device. In order to assess pain reduction, a comparative study will be performed and each subject will serve as his/her own control.

Clinical assessment for all 100% patients will occur at baseline. All participants will be men and women above the age of 18. The trial will be conducted at a Medical Center.

Eligibility Criteria:
Inclusion Criteria:

* Subject is healthy
* Subject's age is between 18 to 70 years old
* Subject must be capable of providing informed consent

Exclusion Criteria:

* Clotting disorders
* Subject has a clinically significant untreated chronic disease which may unable him/ her to participate in the study.
* Subject is taking anti-coagulant medication
* Non-intact finger tip (left middle/ring finger)
* Skin disease on the subject finger
* Abnormal blood pressure
* Pregnant or lactating women
* Menstrual period
* Previous diagnosis of HIV or Hepatitis
* Participation in other clinical investigations within previous 30 days
* Peripheral blood vessels diseases
* Diabetes
* Neuropathic pain
Detection of Colonic Polyps Via a Large Scale Artificial Intelligence (AI) System

Colonoscopy is the gold standard for detection and removal of precancerous lesions, and has been amply shown to reduce mortality. However, the miss rate for polyps during colonoscopies is 22-28%, while 20-24% of the missed lesions are histologically confirmed precancerous adenomas. To address this shortcoming, the investigators propose a new polyp detection system based on deep learning, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy. The investigators dub the system DEEP: (DEEP) DEtection of Elusive Polyps. The DEEP system was trained on 3,611 hours of colonoscopy videos derived from two sources, and was validated on a set comprising 1,393 hours of video, coming from a third, unrelated source. For the validation set, the ground truth labelling was provided by offline gastroenterologist annotators, who were able to watch the video in slow-motion and pause/rewind as required; two or three specialist annotators examined each video.

This is a prospective, non-blinded, non-randomized pilot study of patients undergoing elective screening and surveillance colonoscopies using DEEP.

The aim of the study is to:

Assess the:

1. Number of additional polyps detected by the DEEP system in real time colonoscopy.
2. Safety by prospective assessment of the rate of adverse events during the study period attributed or not to the use of the DEEP system.
3. Stability of the DEEP system by measuring the rate of false positives (False Alarms) per colonoscopies 4 And to examine its feasibility and usefulness of in clinical practice by assessing the colonoscopist user experience while using the DEEP system in a 5 point scale.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects undergoing routine screening or surveillance colonoscopy in an ambulatory non urgent setting.
* Able to understand the study protocol and sign inform consent.

Exclusion Criteria:

* Previous surgery involving the colon or rectum
* Known diagnosis of colorectal cancer
* Known history of inflammatory bowel disease
* Known or suspected diagnosis of familial polyposis syndrome
Safety of HRX215 in Patients After Minor and Major Liver Resection

The goal of this clinical trial is to learn if HRX215 is safe and tolerable in adults who have undergone surgical removal of metastatic tumor(s) due to colorectal carcinoma in the liver.

The main question it aims to answer are:

1. to learn about the safety of HRX215
2. to learn about how the body absorbs, distributes, and gets rid of HRX215 . Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to see what medical problems participants have when taking HRX215.

Participants will:

Take HRX215 or a placebo twice a day for 28 days Daily visits for 7 days for checkups and tests which may either be in the hospital or outpatient after 3 days. Clinic visits every two weeks for the next two visits. The visit at two weeks may be a home visit or clinic visit. Additional clinic visits 3 months and 6 months after the start of treatment

The study is designed to evaluate primarily the safety of HRX215, first after minor liver resection and, when safety is established, in those patients after major liver resection. Participants will start treatment within 1-3 days after liver resection and will receive 28 day treatment with HRX215 twice daily or placebo with follow up visits 3 and 6 months after completion of treatment.

The pharmacokinetics will be compared with the results of the phase I studies, whereas efficacy will be evaluated only descriptively. Secondary objectives will include evaluation of differences in liver volume recovery postoperatively and clinical outcomes including days in the ICU and 90 day mortality in participants who receive treatment with HRX215 vs. placebo.

Eligibility Criteria:
Inclusion Criteria:

1. Stable male and female patients between 18 and 75 years within 1-3 days after extended resection of the right or left liver lobe due to metastases of a colon carcinoma, but otherwise normal liver parenchyma proven by histopathology assessment of a liver biopsy within 3 months before surgery and liver functional parameters.
2. For the pilot phase less extended resections (remnant liver volume \&amp;gt;69%) are required)
3. Percentage of Remnant Liver Volume (RLV) 28%-50% (randomized part of the study)

   -

Exclusion Criteria:

1. Liver Cirrhosis
2. Preoperative presence of clinical ascites
3. Any other liver cancer
4. BMI \&gt;35 kg/m2
5. ASA Score\&gt;4
6. CC Score \&gt;0: all patients with pre-operatively or intra-operatively diagnosed peritoneal carcinosis or other pre-op or intra-op findings which would deem the patient to be unresectable, are excluded.
7. Incomplete liver metastasis resection -
Effects of Graston Technique in Patients With Non Specific Low Back Pain

Non-specific low back pain upsets individuals of all age gathering and is a most significant provider to illness load everywhere on the world. Overseeing rules prescribe emergency to locate the uncommon instances of low back pain that are brought about by actually genuine pathology, thus need demonstrative work-up or proficient arrangement, or both. Since non-specific low back pain doesn't have a known pathoanatomical cause and treatment accentuations on diminishing in agony and its meanings.

To determine the impacts of Graston technique in patients with non-specific low back pain.

This examination was Quasi Experimental study and on the basis of inclusion standards, 20 patients were involved. PNRS and ODI used to collect the data. Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA. The data was analyzed using SPSS 21.


Eligibility Criteria:
Inclusion Criteria:

* • Both genders

  * Age (20-40 years)
  * Patients with non-specific backache
  * Trigger points and tender points at low back region

Exclusion Criteria:

* • Patients with chronic diseases

  * Degenerative changes in spine
  * Open wounds around the area to be treated
  * High blood pressure
  * Diabetic neuropathy
  * Cancer (depending on the type and location)
  * Taking anti-coagulants
  * Pregnancy
Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength, Pain and Mobilization After Total Knee Replacement

The aim of this study is to investigate the efficacy of the Adductor-Canal-Blockade versus the Femoral Nerve Block on muscle strength, pain and mobilization after total knee arthroplasty. We hypothesize that the Adductor-Canal-Blockade has the same effect on pain and morphine consumption as the Femoral Nerve Block, but without the same reduction in quadriceps muscle strength.


Eligibility Criteria:
Inclusion Criteria:

* ASA 1-3
* BMI \> 18 og \< 40
* total knee arthroplasty in spinal anesthesia

Exclusion Criteria:

* Can not cooperate to the exam
* Do not speak or understand Danish
* Drug allergy
* Alcohol or drug abuse
* Daily consumption of strong opioids
* Rheumatoid arthritis
* Intake of glucocorticoids
* Effect of spinal anesthesia stopped prior to performing the regional block
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels. The investigators will also assess whether the immunologic or relevant gene expression response to oral vitamin D supplementation differs in patients with MS and healthy controls.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Healthy or multiple sclerosis
* Aged 18 to 60
* Body mass index is between 18 kg/m2 and 30 kg/m2
* Screening 25-hydroxyvitamin D level ≤ 75 nmol/L (30 ng/mL)
* White race
* Non-Hispanic ethnicity
* Willing to use birth control during study
* Willing to not use tanning bed during study

If subject has multiple sclerosis:

* Relapsing-remitting MS, as defined by McDonald 2005 criteria
* Screening Expanded Disability Status Scale score ≤ 3.0
* Using no medication for MS, or taking Copaxone, (glatiramer acetate), interferons, or natalizumab

Exclusion Criteria:

* Pregnant or nursing
* Taking multivitamin \& unwilling to remain off it during study
* Taking cod liver oil \& unwilling to remain off it during study
* On a fat-restricted diet
* History of renal disease or nephrolithiasis (kidney stones)
* History of liver disease
* Taking thiazide diuretics
* History of hyperthyroidism
* History of infection with Mycobacterium species
* History of sarcoidosis
* History of cancer
* History of cardiac disease
* History of HIV
* History of gastrointestinal disorder
* Taking medications that interfere with gastrointestinal absorption
* Cigarette smoker in past month
* Use of illicit drugs in past month
* Use of steroids in past month
* History of hypercalcemia, and screening serum calcium ≤ 10 mg/dL (UCSF) or ≤ 10.7 mg/dL (Johns Hopkins)
* History of hypercalciuria
* Evidence of anemia (Hgb \<11.0 g/dL)
* History of other serious medical conditions
* Taking medications that involve the P450 system or may interact with vitamin D (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin)
* Other concerns about safety from the perspective of the treating physician

If subject has MS:

-History of major heat sensitivity (leading to sun-avoidant behaviors)
Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation

The aim of this study is to compare two FET protocols by modifying the substituted FET cycle in order to maintain a higher ongoing positive pregnancy rate and thus reduce the early pregnancy loss.

Hypothesis: adding GnRH-agonist to the substituted cycle in FET treatment reduces the early pregnancy loss.


Eligibility Criteria:
Inclusion Criteria:

* Endometrial thickness ≥ 7 mm after stimulation
* 18-45 years
* IVF/ICSI fertilisation
* BMI \> 18,5 \<30 kg/m2
* cycle length 25-34 days

Exclusion Criteria:

* endometrial thickness \< 7 mm or no triple layer endometrium and/or functional follicles
* Uterine abnormality
* Chronic medical disease
* oocyte donation cycles
Skeletal Muscle Atrophy and Dysfunction in Human Cancer

Cancer and its treatment can have profound effects on skeletal muscle, the most well-recognized being atrophy, weakness and diminished oxidative capacity. These adaptations negatively impact quality of life, treatment decisions and survival. Despite these consequences, the factors promoting these adaptations remain poorly defined and understudied in human patients. To address this gap in knowledge, our goal in this study is to examine the role of muscle disuse as a regulator of muscle size and function in human cancer patients


Eligibility Criteria:
Inclusion Criteria:

* 50-75 yrs of age
* histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC)
* estimated life expectancy \>6 mos
* Karnofsky's performance score of ≥70

Exclusion Criteria:

* history, signs or symptoms of inflammatory or autoimmune disease
* uncontrolled hypertension
* heart or renal failure
* exercise limitations from peripheral vascular disease or stroke
* neuromuscular disease
* knee/hip replacement
* additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer
* taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy